Breaking News Instant updates and real-time market news.

AMRS

Amyris

$5.44

-0.035 (-0.64%)

, EOLS

Evolus

$28.87

4.73 (19.59%)

08:45
02/08/19
02/08
08:45
02/08/19
08:45

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Amyris (AMRS) 47.81% +1.31, Evolus (EOLS) 76.07% +0.54, Papa John's (PZZA) 3.92% +0.21, Coty (COTY) 0.35% +0.08, Direxion S&P Biotech Bear 3X (LABD) 9.15% +0.04, Cronos Group (CRON) 35.63% +0.02, Market Vectors Semiconductor (SMH) 1.06% +0.02, NIO Inc (NIO) 46.74% +0.02, ProShares UltraPro QQQ (TQQQ) 0.85% +0.01, and iShares DJ US Home Construction Index Fund (ITB) 1.33% +0.01.

AMRS

Amyris

$5.44

-0.035 (-0.64%)

EOLS

Evolus

$28.87

4.73 (19.59%)

PZZA

Papa John's

$43.47

0.79 (1.85%)

COTY

Coty

$7.06

-0.37 (-4.98%)

LABD

Daily S&P Biotech Bear 3x Shares

$26.60

2.01 (8.17%)

CRON

Cronos Group

$21.38

1.74 (8.86%)

SMH

Market Vectors Semiconductor

$99.11

-2.13 (-2.10%)

NIO

NIO Inc.

$8.01

-0.39 (-4.64%)

TQQQ

ProShares UltraPro QQQ

$46.98

-2.02 (-4.12%)

ITB

iShares U.S. Home Construction ETF

$33.87

0.29 (0.86%)

  • 08

    Feb

  • 21

    Feb

  • 03

    Mar

AMRS Amyris
$5.44

-0.035 (-0.64%)

12/07/18
HCWC
12/07/18
NO CHANGE
HCWC
Amyris financing removes 'important overhang,' says H.C. Wainwright
H.C. Wainwright analyst Amit Dayal reiterated a Buy rating and $11 price target on Amyris, noting that the company announced it has entered into definitive agreements for the sale of $60M of unsecured convertible senior notes, in a private placement with two investors. Dayal said this financing removes an "important overhang" for the company, and believes that Amyris is now positioned to focus on execution during 2019. The analyst added that he is looking forward to more information from the company during the last three weeks of this year, including the announcement of a Chinese licensing agreement.
12/31/18
HCWC
12/31/18
NO CHANGE
Target $11
HCWC
Buy
Amyris news today a 'significant near-term milestone,' says H.C. Wainwright
H.C. Wainwright analyst Amit Dayal maintains a Buy rating on Amyris with an $11 price target after the company entered into a long-term agreement with Xinfu for an upfront payment of $50M and an additional long-term annual share upside based on an existing nutritional product royalty arrangement. Amyris is capitalizing on its relationship with Xinfu to monetize a portion of the long-term royalty opportunity upfront, which should lower quarterly volatility from this "high-margin" revenue stream while continuing to benefit from future royalty payments, Dayal tells investors in a research note. He thinks today's news should be viewed as a "timely delivery of a significant near-term milestone by the management team."
02/05/19
HCWC
02/05/19
NO CHANGE
Target $11
HCWC
Buy
H.C. Wainwright reiterates $11 target on Amyris after $255M cannabinoid deal
Amyris this morning announced a $255M collaboration agreement, its largest yet, with an unnamed partner, for cannabinoid development and licensing, H.C. Wainwright analyst Amit Dayal tells investors in a research note. The analyst reiterates a Buy rating on the shares with an $11 price target. The stock in morning trading is up 42%, or $1.33, to $4.49. Dayal believes the agreement calls for several molecules that will be targeting multiple products and end markets, with the first commercial production taking place in 18-24 months. He thinks the early applications are targeting opportunities in the skin care and beverage markets. Further, with an executed binding term sheet in place leading to the announcement, Dayal sees a "high probability" of the deal closing within the expected timeline. And since the non-psychoactive cannabidiol based molecules developed using Amyris' fermentation technology are likely to bypass the psychoactive tetrahydrocannabinol molecule pathway, the regulatory approval process "should not run afoul of the federal THC related restrictions," the analyst writes. He views today's announcement as an "important signal about the scalability" of Amyris' technology platform to enter large new markets very quickly. The analyst also believes the development timeline is "realistic given that product development has been accelerating at the company."
11/14/18
HCWC
11/14/18
NO CHANGE
Target $11
HCWC
Buy
Amyris price target lowered to $11 from $15 at H.C. Wainwright
H.C. Wainwright analyst Amit Dayal lowered his price target for Amyris to $11 to reflect a more conservative stance on forward projections, including removing around $40M of anticipated annual Vitamin E royalty revenues, following the company's revenue miss in Q3. The analyst, however, keeps a Buy rating on the shares.
EOLS Evolus
$28.87

4.73 (19.59%)

08/02/18
JMPS
08/02/18
NO CHANGE
Target $35
JMPS
Outperform
Evolus price target raised to $35 from $30 at JMP Securities
JMP Securities analyst Donald Ellis raised his price target for Evolus (EOLS) to $35 and reiterates an Outperform rating on the shares following the company's Q2 results. The analyst now assumes that DWP-450 will price at a 10% price discount relative to Allergan's (AGN) Botox versus 20% previously. He notes that DWP-450 will not go to market as simply a "generic" Botox, but rather a branded player with a "with a smart go-to-market strategy." The Evolus management team is "carefully and thoughtfully building an aesthetic only major player in the U.S. cosmetic market," Ellis tells investors in a research note.
09/18/18
CANT
09/18/18
NO CHANGE
Target $35
CANT
Overweight
Evolus selloff yesterday not based on fundamentals, says Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen sees no fundamental reason for the 12% pullback yesterday in shares of Evolus (EOLS). The stock weakness was partly attributed to the "upbeat and well-attended" investor day held by competitor Allergan (AGN) last Friday, Chen tells investors in a research note. The analyst points out that shares of Revance (RVNC), which also competes with Allergan in the botulinum toxin space, dropped yesterday as well. Chen believes Allergan's investor day renewed concerns that the company is and will remain the leading botulinum toxin/aesthetics player in the space. However, this is nothing new and is already priced into Evolus' valuation, Chen contends. The analyst continues to expect the company's launch of DWP-450 in spring 2019 to exceed "modest expectations." She keeps an Overweight rating on the shares with a $35 price target.
10/11/18
MZHO
10/11/18
NO CHANGE
Target $27
MZHO
Buy
Evolus pulled back on misinterpretation of article, says Mizuho
Mizuho analyst Irina Koffler believes investors yesterday may have overreacted to a Korea Herald article dated October 4. The article, which the analyst believes is being taken out of content, said Evolus partner Daewoong had terminated its clinical trial application for its botulinum toxin drug Nabota on plans to refile with another production site. Koffler confirmed with Evolus management that Daewoong is going to make Nabota at the plant that recently passed FDA inspection for DWP-450. The article is being misinterpreted to mean that there is some manufacturing risk to DWP-450 in the U.S., which may be incorrect, Koffler told investors yesterday in a research note. She reiterates a Buy rating on Evolus with a $27 price target. The stock closed yesterday down 10.5%, or $1.72, to $14.71.
01/28/19
STFL
01/28/19
INITIATION
Target $27
STFL
Buy
Evolus initiated with a Buy at Stifel
Stifel analyst Annabel Samimy started Evolus (EOLS) with a Buy rating and $27 price target, citing her view of the potential for Jeuveau to be an identical, drop-in, "frictionless" replacement for Allergan's (AGN) Botox with "a marketing angle and pedigree that no other toxin has claimed before."
PZZA Papa John's
$43.47

0.79 (1.85%)

02/06/19
LBOW
02/06/19
NO CHANGE
Target $52
LBOW
Buy
Papa John's an attractive buyout candidate if SSS recover, says Longbow
Longbow analyst Chris Dankert lowered his price target for Papa John's International to $52 from $61 while maintaining a Buy rating on the shares. The stock closed yesterday up 4%, or $1.78, to $43.75. While "certainly disappointed" with the company's North American same-store sales performance in Q4 and January, the analyst believes Papa John's is in "far better position" to bring customers back following Starboard's capital investment and corresponding board leadership. If and when same-store sales trends "finally recover," Papa John's will represent an attractive acquisition candidate, especially with Mr. Schnatter no longer the face of the brand, Dankert tells investors in a research note.
02/05/19
JEFF
02/05/19
NO CHANGE
Target $53
JEFF
Buy
Jefferies cuts Papa John's target to $53 from $61, sees favorable risk/reward
Jefferies analyst Alexander Slagle lowered his price target for Papa John's International to $53 from $61 and keeps a Buy rating on the shares. The company yesterday preannounced Q4 near the lower end of guidance and same-store-sales were still soft into January, at down 10.5%, Slagle tells investors in a research note. While the company's fundamental progress is slow, the stock's risk/reward is favorable, says the analyst. Further, the Starboard transaction "provides key financial resources and turnaround experience" to support Papa John's brand transformation, contends the analyst.
02/04/19
SPHN
02/04/19
NO CHANGE
Target $55
SPHN
Overweight
Stephens 'encouraged' by Starboard strategic investment in Papa John's
After Starboard Value announced that it is making a $200M strategic investment in Papa John's, Stephens analyst Will Slabaugh said he was "encouraged" by the news given Starboard's track record and he believes the firm can help improve the brand's positioning. While the worse than expected same-store sales declines in both North America and internationally are a negative surprise, he is "hopeful" that new campaigns, menu extensions and loyalty changes can help the same-store sales trajectory. Slabaugh keeps an Overweight rating and $55 price target on Papa John's shares.
02/01/19
STFL
02/01/19
NO CHANGE
Target $38
STFL
Hold
Papa John's price target lowered to $38 from $48 at Stifel
Stifel analyst lowered his Q1 same-restaurant sale projections for Papa John's to down 7% from down 5%, compared to the consensus forecast for a decline of 3.5%, given his view that the company's recent $6 promotion was likely not effective and did not increase transactions enough to offset the negative check impact from the offering. He remains cautious on the stock given the weak domestic sales performance and low franchisee profitability and keeps a Hold rating on Papa John's while cutting his price target to $38 from $48.
COTY Coty
$7.06

-0.37 (-4.98%)

11/15/18
BMOC
11/15/18
UPGRADE
Target $12
BMOC
Outperform
Coty upgraded to Outperform from Market Perform at BMO Capital
BMO Capital analyst Shannon Coyne upgraded Coty to Outperform from Market Perform and kept her price target at $12. The analyst says that her downgrade in August was driven by concerns around the company's supply chain issues, but believes that these factors have now been fully priced in after the management withdrew its guidance and consensus earnings have been pulled back by about 30%. With a 30% decline in the stock price over the past 10 weeks, Coyne states that the risk-reward on shares of Coty is now "compelling".
11/08/18
RBCM
11/08/18
NO CHANGE
Target $18
RBCM
Outperform
Coty price target lowered to $18 from $23 at RBC Capital
RBC Capital analyst Nik Modi lowered his price target on Coty to $18 after its lower than expected sales in Q1. The analyst notes that the market expectations for the company were already low after the management disclosed supply chain disruptions last weakness, adding that investors were further disappointed by "consumer beauty weakness and high leverage". Modi keeps his Outperform rating on Coty but believes that the stock is now more of a "2019 story", anticipating its top line to gradually improve and margins to expand on productivity efforts and synergies from the P&G acquisition.
11/15/18
11/15/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Mylan (MYL) upgraded to Buy from Hold at Argus with analyst Jasper Hellweg saying the stock appears to be close to an inflection after several quarters of underperformance. 2. CopyTele (COPY) upgraded to Outperform from Market Perform at BMO Capital. 3. Voyager Therapeutics (VYGR) upgraded to Strong Buy from Outperform at Raymond James. 4. Athenex (ATNX) upgraded to Overweight from Neutral at JPMorgan with analyst Leon Chik saying more clinical data and progress in new drug trials should boost investor sentiment in 2019. 5. Coty (COTY) upgraded to Outperform from Market Perform at BMO Capital with analyst Shannon Coyne saying that her downgrade in August was driven by concerns around the company's supply chain issues, but believes that these factors have now been fully priced in after the management withdrew its guidance and consensus earnings have been pulled back by about 30%. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/04/19
JPMS
01/04/19
UPGRADE
Target $7
JPMS
Neutral
Coty upgraded to Neutral from Underweight at JPMorgan
JPMorgan analyst Andrea Teixeira upgraded Coty to Neutral with a $7 price target. The analyst's sum-of-the-parts analysis indicates Coty's valuation is "flushed out" at current levels. Teixeira, however, still sees potential downside to consensus estimates.
LABD Daily S&P Biotech Bear 3x Shares
$26.60

2.01 (8.17%)

CRON Cronos Group
$21.38

1.74 (8.86%)

02/05/19
MITR
02/05/19
DOWNGRADE
MITR
Hold
Cronos Group downgraded to Hold from Buy at GMP Securities
02/05/19
02/05/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Rent-A-Center (RCII) downgraded to Neutral from Buy at Janney Montgomery Scott with analyst John Rowan citing the stock's 50% rise from its intra-day low of $11.98 on December 18, 2018. 2. Equifax (EFX) downgraded to Hold from Buy at Deutsche Bank with analyst Ashish Sabadra saying the shares have rallied significantly off the bottom and outperformed the market year-to-date due to expectations for improving mortgage originations and overall consumer lending. 3. Kraft Heinz (KHC) downgraded to Hold from Buy at Deutsche Bank with analyst Rob Dickerson saying his analysis shows store brands continue to increase distribution points and take share in the majority of Kraft Heinz's largest categories. 4. CenturyLink (CTL) downgraded to Sell from Neutral at Citi with analyst Michael Rollins saying he expects headwinds on revenue and cash flow, a possible dividend cut, and the likelihood for capex upgrades to lead to further multiple contraction. 5. Cronos Group (CRON) downgraded to Hold from Buy at GMP Securities with analyst Martin Landry citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/18/19
CIBC
01/18/19
INITIATION
CIBC
Neutral
Aphria initiated with a Neutral at CIBC
CIBC analyst John Zamparo initiated Aphria (APHA) with a Neutral rating and C$10 price target. He expects cannabis to follow the course of other newborn industries, where investors rush to pour capital into the sector and then very few companies live up to their lofty expectations while the industries develop. The debate over the value of Aphria's international assets and corporate governance concerns have obscured the value of the company's quality domestic assets, but concerns about corporate governance and capital allocation are not without some validity, Zamparo tells investors. He also initiated coverage on two other cannabis stocks, Canopy Growth (CGC) and Cronos Group (CRON), both with Outperformer ratings this morning, citing his favorable view of their management teams.
02/05/19
MITR
02/05/19
DOWNGRADE
Target $24
MITR
Hold
Cronos Group downgraded to Hold on valuation at GMP Securities
As previously reported, GMP Securities analyst Martin Landry downgraded Cronos Group to Hold from Buy with a C$24 price target, citing valuation. In a research note to investors, Landry notes that shares yesterday reached an all-time high of $32.95, surging about 110% year-to-date on no material news. He says his downgrade is not based on any operational issues, as he is a believer in Cronos' "bright" outlook and has no concerns on the company's expansion plans or the execution abilities of its management team, but says shares "need a breather" given the significant appreciation in recent weeks.
SMH Market Vectors Semiconductor
$99.11

-2.13 (-2.10%)

NIO NIO Inc.
$8.01

-0.39 (-4.64%)

01/15/19
EGHT
01/15/19
INITIATION
EGHT
Sell
86 Research starts NIO Inc. with a Sell rating, $4.70 price target
86 Research analyst Robert Cowell initiated coverage of NIO Inc. (NIO) with a Sell rating and $4.70 price target, stating that the company offers "attractive" fully electric SUVs at "attractive" prices in China, but is "losing large sums of money by doing so." He has concerns that NIO's operations are not efficient enough and said it does not have the same potential to revolutionize EV manufacturing as Tesla (TSLA) does. Additionally, the company's price advantage for its SUVs over Tesla cars is reliant on government subsidies, noted Cowell.
01/15/19
EGHT
01/15/19
INITIATION
Target $4.7
EGHT
Sell
NIO Inc. initiated with a Sell at 86 Research
86 Research initiated NIO Inc with a Sell adn $4.70 price target.
10/22/18
FBCO
10/22/18
INITIATION
Target $12.6
FBCO
Outperform
Credit Suisse starts NIO Inc. with an Outperform rating, $12.60 price target
Credit Suisse analyst Bin Wang initated NIO Inc. with an Outperform rating and $12.60 price target, stating that the company has a well-establish premium branding in China and is a leader in smart electric vehicle technology. He estimates NIO's revenue will grow at a 192% CAGR to 2020 and sees the company achieving its first year of breakeven in 2021, when Wang assumes it will be able to produce 165,000 units.Target $12.60.
11/06/18
SBSH
11/06/18
NO CHANGE
Target $7.2
SBSH
Neutral
Citi sees three catalysts in three months for shares of NIO
Citi analyst Jeff Chung views NIO Inc.'s Q3 results as generally in-line with consensus and says its Q4 revenue only needs to achieve 70% quarter-over-quarter growth in order to meet his fiscal 2018 forecast, which he believes "carries very high visibility now." The analyst sees three catalysts for the shares in the next months. The first being December ES8 sales and production run-rate accelerating to 30,000 units from November's 23,000-25,000 units. The second being NIO announcing ES6 order backlog status between the end of fiscal 2018 and January 2019. And the third being the company's Q4 earnings report in February 2019. In a best case scenario, Chung expects Q4 revenue up 85% to 110% quarter-over-quarter. He keeps a Neutral rating on NIO Inc. with a $7.20 price target.
TQQQ ProShares UltraPro QQQ
$46.98

-2.02 (-4.12%)

ITB iShares U.S. Home Construction ETF
$33.87

0.29 (0.86%)

TODAY'S FREE FLY STORIES

PYPL

PayPal

$118.65

-1.22 (-1.02%)

, V

Visa

$179.18

-1.34 (-0.74%)

08:31
07/20/19
07/20
08:31
07/20/19
08:31
Periodicals
MasterCard, Visa among best stocks to play fintech boom, Barron's says »

The fintech units within…

PYPL

PayPal

$118.65

-1.22 (-1.02%)

V

Visa

$179.18

-1.34 (-0.74%)

MA

MasterCard

$275.51

-1.11 (-0.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 24

    Jul

  • 30

    Jul

USB

U.S. Bancorp

$54.98

-0.2 (-0.36%)

, SBNY

Signature Bank

$123.87

1.07 (0.87%)

08:28
07/20/19
07/20
08:28
07/20/19
08:28
Periodicals
KeyCorp, U.S. Bancorp better positioned for Fed rate cut, Barron's says »

KeyCorp (KEY), Signature…

USB

U.S. Bancorp

$54.98

-0.2 (-0.36%)

SBNY

Signature Bank

$123.87

1.07 (0.87%)

KEY

KeyCorp

$17.45

0.15 (0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 29

    Aug

  • 16

    Oct

CMG

Chipotle

$746.80

-17.43 (-2.28%)

08:24
07/20/19
07/20
08:24
07/20/19
08:24
Periodicals
Chipotle stock made 'stunning' comeback, Barron's says »

Chipotle's stock is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 25

    Sep

BYND

Beyond Meat

$176.65

6.28 (3.69%)

07:40
07/20/19
07/20
07:40
07/20/19
07:40
Periodicals
Beyond Meat could spike after earnings, Barron's says »

After rising so…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jul

NFLX

Netflix

$315.10

-10.04 (-3.09%)

07:37
07/20/19
07/20
07:37
07/20/19
07:37
Periodicals
Netflix's problems have only just begun, Barron's says »

Netflix has a problem and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

, TGT

Target

$88.02

-0.48 (-0.54%)

07:34
07/20/19
07/20
07:34
07/20/19
07:34
Periodicals
Time to aim higher on Target's stock, Barron's says »

As retailers have…

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

TGT

Target

$88.02

-0.48 (-0.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 21

    Aug

  • 19

    Sep

  • 25

    Sep

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

, FDX

FedEx

$167.08

1.69 (1.02%)

07:31
07/20/19
07/20
07:31
07/20/19
07:31
Periodicals
FedEx ups game amid e-commerce growth, Barron's says »

It is time to embrace…

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

FDX

FedEx

$167.08

1.69 (1.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 30

    Jul

  • 31

    Jul

  • 17

    Sep

  • 13

    Nov

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

, MSFT

Microsoft

$136.62

0.33 (0.24%)

07:27
07/20/19
07/20
07:27
07/20/19
07:27
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

MSFT

Microsoft

$136.62

0.33 (0.24%)

ORCL

Oracle

$57.55

-0.58 (-1.00%)

AZN

AstraZeneca

$40.11

-0.61 (-1.50%)

BMY

Bristol-Myers

$43.32

-0.72 (-1.63%)

LLY

Eli Lilly

$106.75

-1.57 (-1.45%)

GSK

GlaxoSmithKline

$40.97

-0.44 (-1.06%)

JNJ

Johnson & Johnson

$130.41

-1.62 (-1.23%)

MRK

Merck

$81.39

-1.28 (-1.55%)

NVS

Novartis

$93.58

-0.715 (-0.76%)

PFE

Pfizer

$42.78

-0.28 (-0.65%)

RHHBY

Roche

$0.00

(0.00%)

SNY

Sanofi

$41.94

-0.01 (-0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 24

    Jul

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 29

    Jul

  • 30

    Jul

  • 30

    Jul

  • 30

    Jul

  • 03

    Aug

  • 06

    Aug

  • 06

    Aug

  • 08

    Aug

  • 18

    Aug

  • 19

    Aug

  • 26

    Aug

  • 27

    Aug

  • 28

    Aug

  • 02

    Sep

  • 09

    Sep

  • 16

    Sep

  • 16

    Sep

  • 20

    Sep

  • 23

    Sep

  • 25

    Sep

  • 02

    Oct

  • 15

    Oct

  • 04

    Nov

BHVN

Biohaven Pharmaceutical

$44.16

-0.61 (-1.36%)

18:12
07/19/19
07/19
18:12
07/19/19
18:12
Hot Stocks
Biohaven receives CRL from FDA for application seeking NURTEC approval »

Biohaven Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

CE

Celanese

$107.01

0.9 (0.85%)

18:01
07/19/19
07/19
18:01
07/19/19
18:01
Hot Stocks
Celanese announces acetyl intermediates price increases »

Celanese Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

F

Ford

$10.20

-0.06 (-0.58%)

17:48
07/19/19
07/19
17:48
07/19/19
17:48
Periodicals
Ford plans to lay off 185 employees at Ontario plant, Reuters reports »

A union local said that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 23

    Oct

RTN

Raytheon

$178.55

2.45 (1.39%)

17:48
07/19/19
07/19
17:48
07/19/19
17:48
Hot Stocks
Raytheon awarded $191.01M Air Force contract modification »

Raytheon has been awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

UTX

United Technologies

$132.37

1.08 (0.82%)

17:44
07/19/19
07/19
17:44
07/19/19
17:44
Hot Stocks
United Technologies awarded $253.71M Air Force contract »

United Technologies has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

LMT

Lockheed Martin

$356.90

0.675 (0.19%)

17:40
07/19/19
07/19
17:40
07/19/19
17:40
Hot Stocks
Lockheed Martin awarded $1.47B Missile Defense Agency contract modification »

Lockheed Martin has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

ARES

Ares Management

$28.13

-0.305 (-1.07%)

17:33
07/19/19
07/19
17:33
07/19/19
17:33
Syndicate
Breaking Syndicate news story on Ares Management »

Ares Management files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

  • 06

    Aug

HAFC

Hanmi Financial

$21.68

-0.105 (-0.48%)

17:33
07/19/19
07/19
17:33
07/19/19
17:33
Hot Stocks
Hanmi Financial to delay release of Q2 results »

Hanmi Financial announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

PAYS

Paysign

$17.49

-0.48 (-2.67%)

17:32
07/19/19
07/19
17:32
07/19/19
17:32
Syndicate
Breaking Syndicate news story on Paysign »

Paysign files $150M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MEOH

Methanex

$43.19

0.83 (1.96%)

17:28
07/19/19
07/19
17:28
07/19/19
17:28
Hot Stocks
Methanex reaches final investment decision on methanol plant in Geismar, LA »

Methanex Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

17:17
07/19/19
07/19
17:17
07/19/19
17:17
Conference/Events
Credit Suisse biotech analysts to hold an analyst/industry conference call »

Biotech Analysts provide…

17:14
07/19/19
07/19
17:14
07/19/19
17:14
Conference/Events
UBS retail/hardlines analyst to hold an analyst/industry conference call »

Retail/Hardlines Analyst…

SHIP

Seanergy Marine

$0.64

-0.0425 (-6.25%)

17:05
07/19/19
07/19
17:05
07/19/19
17:05
Hot Stocks
Seanergy Maritime receives noncompliance notice from Nasdaq »

Seanergy Maritime…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SONM

Sonim

$13.42

0.24 (1.82%)

16:41
07/19/19
07/19
16:41
07/19/19
16:41
Conference/Events
Sonim management to meet with Oppenheimer »

Meetings to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 25

    Jul

  • 26

    Jul

  • 12

    Sep

KINS

Kingstone Companies

$8.81

0.09 (1.03%)

16:30
07/19/19
07/19
16:30
07/19/19
16:30
Hot Stocks
Kingstone names Barry Goldstein CEO »

Kingstone Companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Aug

  • 09

    Aug

16:30
07/19/19
07/19
16:30
07/19/19
16:30
Options
Preliminary option volume of 22.6M today »

Preliminary option volume…

BA

Boeing

$377.34

16.17 (4.48%)

, MSFT

Microsoft

$136.62

0.33 (0.24%)

16:24
07/19/19
07/19
16:24
07/19/19
16:24
On The Fly
Fly Intel: Wall Street's top stories for Friday »

Stocks were tentatively…

BA

Boeing

$377.34

16.17 (4.48%)

MSFT

Microsoft

$136.62

0.33 (0.24%)

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

AAPL

Apple

$202.62

-3.02 (-1.47%)

WMT

Walmart

$113.91

-0.77 (-0.67%)

DIS

Disney

$139.86

-1.76 (-1.24%)

GCI

Gannett

$9.43

1.53 (19.37%)

CRWD

Crowdstrike

$83.50

10.75 (14.78%)

SKX

Skechers

$39.00

4.25 (12.23%)

PACB

Pacific Biosciences

$5.34

-0.53 (-9.03%)

ILMN

Illumina

$293.10

-5.44 (-1.82%)

CHWY

Chewy

$30.70

-2.09 (-6.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 25

    Jul

  • 29

    Jul

  • 30

    Jul

  • 03

    Aug

  • 06

    Aug

  • 06

    Aug

  • 08

    Aug

  • 15

    Aug

  • 03

    Sep

  • 25

    Sep

  • 13

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.